Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2025 | $15.00 | Outperform | Leerink Partners |
| 12/13/2024 | Equal-Weight → Underweight | Morgan Stanley | |
| 3/15/2024 | $20.00 → $15.00 | Buy | Needham |
| 3/15/2024 | Outperform → Market Perform | TD Cowen | |
| 3/15/2024 | $16.00 → $3.00 | Buy → Hold | Jefferies |
| 12/1/2023 | $20.00 | Buy | Needham |
| 6/26/2023 | $25.00 | Outperform | Oppenheimer |
| 4/19/2023 | $5.00 → $14.00 | Underweight → Equal-Weight | Morgan Stanley |
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Mr. Gengos most recently served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for $6.7 billion. At Immuneering, Mr. Gengos will oversee financial strategy, capital allocation, in
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endpoint of overall survival, anticipated in mid-2028 NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that the first patient has been dosed in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer patien
- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treatment-related adverse events occurring in ≥10% of patients, both chemotherapy related - - 84% of participants maintained or gained weight at three months - - Global Phase 3 MAPKeeper 301 trial (NCT07562152) in first-line metastatic pancreatic cancer actively recruiting, with first patient dosing expected in mid-2026 - - Company to hold investor conference call today, at 8:00 a.m. EDT - NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical
8-K - Immuneering Corp (0001790340) (Filer)
8-K - Immuneering Corp (0001790340) (Filer)
8-K - Immuneering Corp (0001790340) (Filer)
Leerink Partners initiated coverage of Immuneering with a rating of Outperform and set a new price target of $15.00
Morgan Stanley downgraded Immuneering Corporation from Equal-Weight to Underweight
Needham reiterated coverage of Immuneering Corporation with a rating of Buy and set a new price target of $15.00 from $20.00 previously
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion. His career
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE
CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors. "On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board," said Ben Zeskind, Chief Executive Officer, Immuneering Corporation. "Tom's extensive experience developing new medicines, including 25 years guiding drug discovery, development and commercialization
- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treatment-related adverse events occurring in ≥10% of patients, both chemotherapy related - - 84% of participants maintained or gained weight at three months - - Global Phase 3 MAPKeeper 301 trial (NCT07562152) in first-line metastatic pancreatic cancer actively recruiting, with first patient dosing expected in mid-2026 - - Company to hold investor conference call today, at 8:00 a.m. EDT - NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical
- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment-related adverse events observed in ≥10% of patients, both chemotherapy-related - - Company to hold investor conference call on June 1, 2026, at 8:00 a.m. EST - NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported a 17.3-month median overall survival (OS) in first-line metastatic pancreatic cancer patients treated in its Phas
- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026 - - Company to host conference call at 4:30 p.m. ET today - NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping
SC 13G/A - Immuneering Corp (0001790340) (Subject)
SC 13G/A - Immuneering Corp (0001790340) (Subject)
SC 13G/A - Immuneering Corp (0001790340) (Subject)